Effects of a lysophosphatidic acid receptor 1 antagonist on hypertensive renal injury in Dahl-Iwai salt-sensitive rats

A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease

(2021) Lucia Del Vecchio et al.   DRUGS

Chronic kidney disease

(2021) Kamyar Kalantar-Zadeh et al.   LANCET

Antidepressants induce profibrotic responses via the lysophosphatidic acid receptor LPA1

(2020) Maria C. Olianas et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Molecular mechanism of lysophosphatidic acid-induced hypertensive response

(2019) Kuniyuki Kano et al.   Scientific Reports

Lysophosphatidic acid receptor 1 inhibitor, AM095, attenuates diabetic nephropathy in mice by downregulation of TLR4/NF-κB signaling and NADPH oxidase

(2019) Jong Han Lee et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Renoprotective effects of sodium-glucose cotransporter-2 inhibitors and underlying mechanisms

(2019) Naoki Kashihara et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Dialysis versus Medical Management at Different Ages and Levels of Kidney Function in Veterans with Advanced CKD

(2018) Manjula Kurella Tamura et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial

(2018) Toby M Maher et al.   Lancet Respiratory Medicine

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis

(2018) Scott M. Palmer et al.   CHEST

Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis

(2017) Nicolas Desroy et al.   JOURNAL OF MEDICINAL CHEMISTRY

Lysophosphatidic Acid Receptor Antagonism Protects against Diabetic Nephropathy in a Type 2 Diabetic Model

(2017) Ming-Zhi Zhang et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Blocking lysophosphatidic acid receptor 1 signaling inhibits diabetic nephropathy in db/db mice

(2017) Hui Ying Li et al.   KIDNEY INTERNATIONAL

Quality of Life of Patients with Advanced Chronic Kidney Disease Receiving Conservative Care without Dialysis

(2016) Mi-Kyung Song   SEMINARS IN DIALYSIS

Prevalence and incidence of chronic kidney disease stage G5 in Japan

(2014) Kunihiro Yamagata et al.   Clinical and Experimental Nephrology

Lysophosphatidic acid as a lipid mediator with multiple biological actions

(2014) S. Aikawa et al.   JOURNAL OF BIOCHEMISTRY

LPA receptor signaling: pharmacology, physiology, and pathophysiology

(2014) Yun C. Yung et al.   JOURNAL OF LIPID RESEARCH

Regulation of T Cell Motility In Vitro and In Vivo by LPA and LPA2

(2014) Sara A. Knowlden et al.   PLoS One

Necessity of Lysophosphatidic Acid Receptor 1 for Development of Arthritis

(2013) Yoshishige Miyabe et al.   ARTHRITIS AND RHEUMATISM

Elevated Serum Levels of Arachidonoyl-lysophosphatidic Acid and Sphingosine 1-Phosphate in Systemic Sclerosis

(2012) Akira Tokumura et al.   International Journal of Medical Sciences

Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma

(2011) Flavia V. Castelino et al.   ARTHRITIS AND RHEUMATISM

Lipoprotein-Derived Lysophosphatidic Acid Promotes Atherosclerosis by Releasing CXCL1 from the Endothelium

(2011) Zhe Zhou et al.   Cell Metabolism

TNF-α promotes LPA1- and LPA3-mediated recruitment of leukocytes in vivo through CXCR2 ligand chemokines

(2011) Chenqi Zhao et al.   JOURNAL OF LIPID RESEARCH

A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model

(2010) JS Swaney et al.   BRITISH JOURNAL OF PHARMACOLOGY

Pharmacokinetic and Pharmacodynamic Characterization of an Oral Lysophosphatidic Acid Type 1 Receptor-Selective Antagonist

(2010) J. S. Swaney et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis

(2010)   LANCET